Clinical trials: Basal Cell Carcinoma of Skin
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
This phase II trial studies how well low dose, reduced frequency nivolumab works in treating patients with cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT07576725
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- Uganda
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Skin Carcinoma
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
RATIONALE: Drugs used in chemotherapy, such as tazarotene, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00783965
- Testing
- tazarotene
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Cutaneous Basal Cell Carcinoma
Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma
Basal cutaneous cell carcinoma (BCC) is the most common skin cancer. Early-stage disease is managed with surgery or radiation that cure more than 95% of patients.
- Trial name
- CEMIQUID (NCT07251413)
- Testing
- cemiplimab, Topical imiquimod
- Where
- 4 sites in Spain
- Volunteers
- 18 people
- Sponsor
- Instituto Oncológico Dr Rosell
Basal Cell Carcinoma
Differential Mobility Spectrometry (DMS) Based Skin Tumor Analysis
The trial is a single-center, non-randomized feasibility study aiming to evaluate the feasibility of ex-vivo tissue analysis using differential mobility spectrometry (DMS) of tissue smoke generated by the use of an…
- Trial name
- NCT05247710
- Testing
- Punch biopsy
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Tampere University Hospital
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Superficial Basal Cell Carcinoma
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC
The purpose of this study is to determine maximum tolerated dose level (MTD) of PEP005 Topical Gel for the treatment of superficial basal cell carcinoma on the trunk
- Trial name
- NCT00432185
- Testing
- PEP005
- Where
- 9 sites in United States
- Volunteers
- 117 people
- Sponsor
- Peplin
Basal Cell Carcinoma of Skin, Squamous Cell Carcinoma (Skin)
Machine Learning Analysis of Two-photon Fluorescence Microscopy of Dermatologic Biopsies
The goal of this study is to investigate the ability of a machine learning model to evaluate two-photon fluorescence microscopy images of dermatologic biopsies at point of care.
- Trial name
- NCT07682831
- Testing
- Two photon microscopy imaging
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- University of Rochester
BCC
Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study
This study is single-arm, none randomized, open label, two-dose-cohorts, single center clinical trial for evaluation of the safety and efficacy of Oshadi D and Oshadi R in patients with BCC.
- Trial name
- NCT02007317
- Testing
- Oshadi D & Oshadi R
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Oshadi Drug Administration
Squamous Cell Carcinoma, Basal Cell Carcinoma
Molecular Characterization of Cutaneous Tumors
The objective is to find genes which are responsible for the appearance of skin tumors (sCC, BCC) and it will be the basis for prediction of the disease and response to the treatment
- Trial name
- NCT03092830
- Testing
- Molecular testing of DNA/RNA from skin tumors, SCC/BCC
- Where
- Israel
- Volunteers
- 500 people
- Sponsor
- Rabin Medical Center
Cutaneous Squamous Cell Carcinoma (CSCC), Basal Cell Carcinoma (BCC)
Flash Radiotherapy for Skin Cancer
The goal of this clinical investigation is to describe and compare the toxicity and efficacy of an experimental radiotherapy, named FLASH therapy, to conventional radiotherapy for subjects suffering from localized Cutaneous…
- Trial name
- LANCE (NCT07455331)
- Testing
- FLASH radiotherapy, Conventional radiotherapy
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- Jules Bordet Institute
Basal Cell Carcinoma
New Imaging Procedures and Therapeutic Approach in Basal Cell Carcinoma Management
The aim of this study is to show that the Nd:YAG laser could be a promising alternative treatment option in the management of low-risk basal cell carcinomas with similar high efficacy rates to surgery, and low recurrence rates…
- Trial name
- NCT05324202
- Testing
- Cynosure Cynergy Nd:YAG Laser 1064nm
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Dr. Stephanie Geisler
Skin Basal Cell Carcinoma
Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer
This pilot clinical trial studies how well arsenic trioxide and itraconazole work in treating patients with basal cell cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment.
- Trial name
- NCT02699723
- Testing
- Arsenic Trioxide, Itraconazole, Laboratory Biomarker Analysis
- Sponsor
- Jean Yuh Tang
Cutaneous Melanoma, Mucosal Melanoma
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability.
- Conditions
- Cutaneous Melanoma, Mucosal Melanoma, Cutaneous Squamous Cell Carcinoma (CSCC), Merkel Cell Carcinoma of Skin
- Trial name
- NCT07600476
- Testing
- KUP-101A
- Where
- 3 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Kupando GmbH
Skin Neoplasms, Carcinoma, Basal Cell
Spanish Registry of Mohs Surgery
REGESMOHS (Registro Español de cirugía de Mohs) aims at describing effectiveness of Mohs surgery, and patient, tumor and technique factors related to adverse events and tumor recurrence.
- Conditions
- Skin Neoplasms, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Dermatofibrosarcoma
- Trial name
- REGESMOHS (NCT02310503)
- Testing
- Mohs surgery
- Where
- 15 sites in Spain
- Volunteers
- 6,000 people
- Sponsor
- Fundación Academia Española de Dermatología
Bladder Cancer, Breast Cancer
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00002520
- Testing
- nicotine, Usual Care
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Eastern Cooperative Oncology Group
Basal Cell Carcinoma in Basal Cell Nevus Syndrome
Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)
The primary objective is to confirm the safety of treating multiple BCCs once weekly x 3 weeks in individuals with Basal Cell Nevus Syndrome (BCNS).
- Trial name
- NCT03208296
- Testing
- ASN-002
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ascend Biopharmaceuticals Ltd
Skin Neoplasms, Carcinoma, Basal Cell
New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)
Basal cell carcinoma (BCC) is the most common malignant skin lesion in white adults. It is a slow-growing tumour which despite low metastatic potential may cause significant local tissue destruction and patient morbidity.
- Trial name
- NCT01482104
- Testing
- MAL-PDT re-treatment, usual MAL-PDT
- Where
- 9 sites in Norway
- Volunteers
- 277 people
- Sponsor
- Norwegian University of Science and Technology
Basal Cell Carcinoma
Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma
Collect real world safety data on the use of sonidegib in adult patients with laBCC. Document major safety parameters such as on treatment deaths, adverse events (AEs)/ serious adverse events (SAEs) and discontinuation secondary…
- Trial name
- NISSO (NCT04066504)
- Testing
- sonidegib
- Where
- 47 sites in Germany, Italy and 2 more
- Volunteers
- 323 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Skin Basal Cell Carcinoma
Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer
This phase 2 trial studies how well remetinostat works in treating patients with skin basal cell cancer. Remetinostat may slow the growth of basal cell cancer cells.
- Trial name
- NCT03180528
- Testing
- Remetinostat
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Kavita Sarin
Breast Cancer, Colorectal Cancer
Family Quality of Life Among Families With a Member Who is a Cancer Patient
RATIONALE: Developing a questionnaire that can be used to assess the quality of life among people who have a family member with cancer may help the study of cancer in the future.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00544336
- Testing
- questionnaire administration, survey administration, quality-of-life assessment
- Where
- 3 sites in United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center